Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IFM Therapeutics

Division of Bristol-Myers Squibb Co.
www.ifmthera.com

Latest From IFM Therapeutics

Targeting Exciting Inflammasome Field, NodThera Raises $55m

UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.

Europe United Kingdom

Novartis Dives Into Inflammasome Pool With IFM Tre Purchase

The Swiss major has bought a US biotech that specializes in targeting the NLRP3 pathway in a deal valued at up to $1.58bn.

M & A Inflammation

Fresh Funding Pushes Inflazome Into Clinic With Inflammation Inhibitors

With $46m funding fresh in its pocket, Dublin biotech Inflazome tells Scrip how it will advance its clinical candidates in multiple indications.

Inflammation Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Bristol-Myers Squibb Co.
  • Senior Management
  • Gary D Glick, PhD, CEO
    Shomir Ghosh, PhD, CSO
    Jim Hampe, SVP, Bus. Dev, Operations, & Strategy
  • Contact Info
  • IFM Therapeutics
    Phone: (781) 267-4858
    855 Boylston St.
    11th Fl.
    Boston, MA 02116
    USA
UsernamePublicRestriction

Register